7 citations
,
September 1991 in “Journal of Andrology” 4‐MAPC reduces rat prostate weight and prostatein levels.
July 2023 in “World Journal of Biology Pharmacy and Health Sciences” Trazodone and Chlorpromazine might help treat sexual dysfunction from finasteride and SSRIs.
19 citations
,
April 2011 in “Headache The Journal of Head and Face Pain” Both topiramate and divalproex sodium effectively reduce migraine frequency and are generally well-tolerated.
1 citations
,
December 1970 in “European journal of endocrinology” Reversed sequential therapy with cyproterone acetate was effective for treating women with hirsutism and related conditions.
February 2006 in “PubMed” Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
July 2026 in “Cosmoderma” Tapering and stopping tofacitinib may be possible for young alopecia areata patients.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
25 citations
,
January 2006 in “Pharmacoepidemiology and drug safety” SSRIs can cause hair loss, especially sertraline, with higher risk in women.
8 citations
,
January 2017 in “Dermatology online journal” Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
April 2018 in “The Journal of Urology” Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
January 2018 in “Repositorio de Tesis - UNMSM” Physalis peruviana extract is more effective in treating benign prostatic hyperplasia in rats than finasteride and terazosine.
13 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
136 citations
,
April 2013 in “Clinical Cancer Research” The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
3 citations
,
October 2024 in “Frontiers in Pharmacology” Compounds from Pterocarpus indicus may help treat benign prostatic hyperplasia by stopping cell growth.
1 citations
,
January 2024 in “NPJ breast cancer” Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
9 citations
,
September 2010 in “Dermatologic therapy” Combining cetirizine and topical steroids can effectively manage severe lichen planus pilaris.
2 citations
,
June 2024 in “Dermatology” Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
November 2025 in “Cochrane Database of Systematic Reviews” Cyproterone acetate works similarly to other treatments for hirsutism, but more research is needed.
13 citations
,
April 2020 in “European Journal of Dermatology” Apremilast showed mixed results for treating severe alopecia areata.
149 citations
,
June 2002 in “Veterinary record/The veterinary record” Trilostane effectively improved symptoms in dogs with a certain adrenal gland disorder.
June 2026 in “Drugs in Context” Deucravacitinib effectively treats psoriasis and may help with other skin conditions.
1 citations
,
October 2023 in “Clinical, cosmetic and investigational dermatology” Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
May 2023 in “International Journal of Trichology” Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.